100
Participants
Start Date
July 4, 2022
Primary Completion Date
December 26, 2023
Study Completion Date
June 12, 2024
Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
Patients enrolled in the study and accessing the HIV consultation will start treatment with BIKTARVY on the day of enrollment. Medication will be provided by the sponsor and dispensed through the pharmacy service. The drug will be delivered to the patient with a delegated person outside the hospital environment or it will be the patient himself who picks up the medication.
H. Infanta Leonor, Madrid
Fundacion SEIMC-GESIDA
OTHER